Related references
Note: Only part of the references are listed.In Vitro Activity of Ceftaroline against Gram-Positive and Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children
Catherine Liu et al.
CLINICAL INFECTIOUS DISEASES (2011)
Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient-a review of the literature
S. J. van Hal et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2011)
Ceftaroline: a comprehensive update
Darpan Kaushik et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates
Celine Vidaillac et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Ceftaroline: A New Cephalosporin with Activity Against Resistant Gram-Positive Pathogens
Molly E. Steed et al.
PHARMACOTHERAPY (2010)
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis, model
Cedric Jacqueline et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Share Paper
